Experimental and Clinical Pharmacology, Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, Postboks 6050, 9037, Langnes, Tromsø, Norway.
Clyde Biosciences, Newhouse, Scotland.
Scand J Trauma Resusc Emerg Med. 2023 Oct 25;31(1):61. doi: 10.1186/s13049-023-01134-5.
Accidental hypothermia, recognized by core temperature below 35 °C, is a lethal condition with a mortality rate up to 25%. Hypothermia-induced cardiac dysfunction causing increased total peripheral resistance and reduced cardiac output contributes to the high mortality rate in this patient group. Recent studies, in vivo and in vitro, have suggested levosimendan, milrinone and isoprenaline as inotropic treatment strategies in this patient group. However, these drugs may pose increased risk of ventricular arrhythmias during hypothermia. Our aim was therefore to describe the effects of levosimendan, milrinone and isoprenaline on the action potential in human cardiomyocytes during hypothermia.
Using an experimental in vitro-design, levosimendan, milrinone and isoprenaline were incubated with iCell hiPSC-derived cardiomyocytes and cellular action potential waveforms and contraction were recorded from monolayers of cultured cells. Experiments were conducted at temperatures from 37 °C down to 26 °C. One-way repeated measures ANOVA was performed to evaluate differences from baseline recordings and one-way ANOVA was performed to evaluate differences between drugs, untreated control and between drug concentrations at the specific temperatures.
Milrinone and isoprenaline both significantly increases action potential triangulation during hypothermia, and thereby the risk of ventricular arrhythmias. Levosimendan, however, does not increase triangulation and the contractile properties also remain preserved during hypothermia down to 26 °C.
Levosimendan remains a promising candidate drug for inotropic treatment of hypothermic patients as it possesses ability to treat hypothermia-induced cardiac dysfunction and no increased risk of ventricular arrhythmias is detected. Milrinone and isoprenaline, on the other hand, appears more dangerous in the hypothermic setting.
体温低于 35°C 被认为是意外低体温,死亡率高达 25%。低温导致的心脏功能障碍引起总外周阻力增加和心输出量减少,是导致该患者群体死亡率高的原因。最近的体内和体外研究表明,左西孟旦、米力农和异丙肾上腺素可作为该患者群体的正性肌力治疗策略。然而,这些药物在低温时可能会增加室性心律失常的风险。因此,我们的目的是描述左西孟旦、米力农和异丙肾上腺素对低温下人诱导多能干细胞衍生的心肌细胞动作电位的影响。
采用实验性体外设计,将左西孟旦、米力农和异丙肾上腺素孵育于 iCell hiPSC 衍生的心肌细胞中,并从单层培养细胞中记录细胞动作电位波形和收缩。实验在 37°C 降至 26°C 的温度下进行。采用单向重复测量方差分析评估与基线记录的差异,采用单向方差分析评估药物之间、未处理对照之间以及特定温度下药物浓度之间的差异。
米力农和异丙肾上腺素均显著增加低温下的动作电位三角化,从而增加室性心律失常的风险。然而,左西孟旦不会增加三角化,并且在 26°C 的低温下,其收缩特性仍然保持。
左西孟旦仍然是低温患者正性肌力治疗的有前途的候选药物,因为它具有治疗低温诱导的心脏功能障碍的能力,并且没有检测到增加室性心律失常的风险。米力农和异丙肾上腺素在低温环境下似乎更危险。